Organic Active Ingredients TRIZ Cases

Segmented VHH constructs reactivate ROS signaling pathways to induce tumor apoptosis at lower concentrations than conventional antibodies.

A nucleic acid-polysaccharide complex formed by phosphorothioated polydeoxyadenine and siRNA bound to schizophyllan.

Reversible furo[3,4-b]pyrrole compounds inhibit BTK to overcome drug resistance mutations while reducing off-target side effects.

Synthesized ferrocene derivatives featuring isoxazole heterocycles target cancer cells through specific structural modifications.

Polar substitutions block blood-brain barrier crossing to treat diabetes without central toxicity.

Bis-substituted nucleosides enhance nuclease resistance while maintaining high affinity for target RNA hybridization.

Tricyclic ATR inhibitors exploit p53 mutations to selectively kill cancer cells while sparing normal tissue from toxicity.

Flavanone derivatives stabilize BKCa channel open forms to reduce bladder smooth muscle excitability and voiding frequency without off-target side effects.

Combines brexpiprazole partial agonist activity with nalmefene opioid antagonism to suppress impulsive ethanol intake.

Specific small molecules disrupt the Hec1/Nek2 interaction, resolving toxicity and solubility issues in cancer treatment.

Formulations with active compounds inhibit Candida progression and alleviate symptoms where current options lack effectiveness.

A topical immunomodulatory substance interacts with peripheral blood mononuclear cells in the skin to treat inflammatory diseases.

Pharmacologic agents reverse adult T cell differentiation to restore proliferative potential, addressing limits of advanced cellular states in adoptive therapy.

Tocopherol phosphoric acid esters increase heme oxygenase expression to remove pigmentary deposits.

CRISPR/Cas systems modify gamma-globin regulatory elements to increase fetal hemoglobin production.

Hyaluronic acid replaces experimental inhibitors to treat ferroptosis-related diseases with improved clinical safety and synergistic effects.

A cross-linked gel barrier layer derived from fatty acids provides a physical anti-adhesion shield on medical implants.

CXCR4 antagonists mobilize stem cells to repair irradiated tissues, resolving G-CSF toxicity and patient non-response issues.

Combining a SMARCA2 degrader with a PD-1 inhibitor overcomes insufficient anti-tumor activity from monotherapy by inducing synthetic lethality.

Novel indole derivative acts as potent CRTH2 inhibitor, reducing side effects compared to Ramatroban.

A prodrug design featuring a cleavable linking cap with electron-withdrawing fluorine substituents on the disulfide linkage.

A formylation and cyclization process produces perampanel without palladium catalysts.

SDC-TRAP conjugates deliver cytotoxic agents to target cells via selective binding moieties, reducing systemic toxicity.

Partially unfolded polypeptides bind fatty acid salts to activate tumor-specific ion channels, inducing cell death while sparing healthy tissue.

Combining antiretroviral drugs with anti-oxidative acids creates stable solid forms that overcome poor oral bioavailability and low plasma concentrations.

IKZF2 degraders selectively reduce regulatory T cell protein levels, enhancing tumor targeting while minimizing systemic toxicity.

A 5-terminal phosphorus moiety protects modified oligonucleotides from nuclease degradation while they hybridize to C9orf72 hexanucleotide repeats.

Cryo-shocked dead cells deliver chemotherapy to bone marrow while stimulating immune responses to prevent acute myeloid leukemia relapse.

Segmented lentiviral vectors eliminate immunostimulatory genes to reduce host immune responses while maintaining transduction capability.

Synergizes zinc pyrithione with optimized iron chelators to overcome limited antifungal efficacy caused by poor membrane permeability.

Airway delivery of interferon-beta and lambda reduces cytotoxicity in elderly smokers by compensating for deficient innate immunity.

Calcination creates a metal hydroxide composite that increases solubility and dispersibility of poorly soluble drugs, maintaining therapeutic concentrations.

Administering erdafitinib with cetuximab restores therapeutic effectiveness in head and neck cancers resistant to single-agent EGFR inhibition.

A PROTAC compound bridges estrogen receptors to VHL ligase for targeted degradation.

GPR40 receptor agonists regulate blood glucose levels without causing hypoglycemia or liver failure.

Novel triazolone and tetrazolone derivatives inhibit Rho kinase activity to address treatment resistance in hypertension and fibrotic diseases.

Formula I compounds suppress the MYC pathway by selectively binding BRD4, reducing proliferation of AML and solid tumor cells.

Anti-FSTL1 antibody targets upstream FSTL1 signaling to suppress regulatory T cell expansion and mitigate bone metastasis.

Spray drying creates three-dimensional porous microparticles that resolve stability and loading contradictions while enabling sustained release.